Core Thesis - Travere Therapeutics, Inc. is positioned as a compelling investment opportunity due to its focus on rare kidney and metabolic diseases, particularly with its lead asset FILSPARI targeting IgA Nephropathy and Focal Segmental Glomerulosclerosis [3][6] Company Overview - Travere Therapeutics specializes in rare kidney and metabolic diseases, with FILSPARI being the first oral, non-immunosuppressive therapy designed to block both Angiotensin II and Endothelin-1 pathways simultaneously [3] - The company’s share price was $30.07 as of February 9th, with a forward P/E ratio of 26.32 [1] Product Pipeline - FILSPARI has shown efficacy in preserving kidney function better than existing therapies, potentially becoming the standard of care and displacing generic alternatives [3] - FSGS represents a high-reward opportunity with an FDA PDUFA date set for April 2026, which could make FILSPARI the only treatment available for this disease [4] - Travere is also developing pegtibatinase for Homocystinuria, which has shown robust reductions in homocysteine levels in early studies, although its pivotal Phase 3 trial has been delayed due to manufacturing challenges [4] Financial Position - The company has a cash position of approximately $323 million, providing a runway into 2027 and mitigating near-term dilution risk [5] - Multiple patent families protect FILSPARI, pegtibatinase, and other assets, with orphan drug exclusivity enhancing market position [5] Competitive Landscape - Travere faces competition from companies like Novartis and Vertex, but its first-mover advantage in the dual Endothelin-Angiotensin receptor antagonist class positions it for significant upside [6] - Potential royalty streams from Asia could further enhance the company's financial outlook [6] Investment Outlook - If FILSPARI secures FSGS approval and pegtibatinase successfully resumes its trial, Travere could transition toward profitability and establish a foundational presence in rare kidney and metabolic diseases [6] - The company is viewed as a high-risk, high-reward investment opportunity in the biotech sector [6]

Core Thesis - Travere Therapeutics, Inc. (TVTX) is positioned as a compelling investment opportunity due to its focus on rare kidney and metabolic diseases, particularly with its lead asset FILSPARI targeting IgA Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) [3][6] Company Overview - Travere Therapeutics specializes in rare kidney and metabolic diseases, with FILSPARI being the first oral, non-immunosuppressive therapy designed to block both Angiotensin II and Endothelin-1 pathways simultaneously [3] - The drug has shown better efficacy in preserving kidney function compared to existing therapies, potentially becoming the standard of care and displacing generic alternatives [3] Market Opportunity - FSGS represents a high-reward opportunity, with an FDA PDUFA date set for April 2026; approval would make FILSPARI the only available treatment for a disease currently lacking options [4] - The company also has a promising enzyme replacement therapy, pegtibatinase, for Homocystinuria (HCU), which has shown robust reductions in homocysteine levels in early studies, although manufacturing challenges have delayed its pivotal Phase 3 trial [4] Financial Position - Travere's cash position is approximately $323 million, providing an expected runway into 2027, which mitigates near-term dilution risk and supports ongoing pipeline development [5] - The company holds multiple patent families protecting its key assets, with orphan drug exclusivity enhancing its market position [5] Competitive Landscape - While facing competition from companies like Novartis and Vertex, Travere's first-mover advantage in the dual Endothelin-Angiotensin receptor antagonist class, along with potential royalty streams from Asia, positions it for significant upside [6] - If FILSPARI secures FSGS approval and pegtibatinase successfully resumes its trial, Travere could transition toward profitability and establish a foundational presence in the rare kidney and metabolic disease market [6]

Core Insights - Travere Therapeutics reported record demand for FILSPARI in the fourth quarter, with 908 new patient starts, indicating growing physician confidence and increased adoption among both new and established prescribers [2][4][6] - The company highlighted strong revenue growth for FILSPARI, generating $103.3 million in Q4 and $322 million for the full year 2025, despite the entry of additional therapies into the market [6][17] - The FDA's review timeline for FILSPARI's supplemental indication in focal segmental glomerulosclerosis (FSGS) has been extended to April 13, 2026, due to a major amendment [6][8] Demand and Adoption - The demand for FILSPARI is attributed to its unique profile as a once-daily oral, non-immunosuppressive therapy, along with simplified monitoring requirements and alignment with KDIGO guidelines [1][4] - Adoption is particularly increasing among IgAN patients with proteinuria levels below 1.5 grams per gram, consistent with guidelines advocating for earlier intervention [1][6] Financial Performance - For Q4 2025, Travere reported U.S. net product sales of $126.6 million, with FILSPARI contributing significantly to this figure [17] - The company achieved a net income of $2.7 million in Q4 2025, a significant improvement from a net loss of $60.3 million in the same quarter the previous year [18] Research and Development - Travere has resumed global site activation for the pivotal Phase 3 HARMONY study of pegtibatinase in classical homocystinuria (HCU), with dosing expected to restart soon [5][16] - The company remains confident in FILSPARI's clinical profile for FSGS, supported by strong results from Phase 2 and Phase 3 studies [11][12] Market Outlook - Management anticipates continued growth in net product sales for FILSPARI, with gross-to-net discounts expected to increase to the mid-20% range for 2026 [20] - Operating expenses are projected to grow moderately in 2026, driven by the execution of ongoing studies and commercial investments [20]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported U.S. net product sales of $126.6 million, with total net product sales for the full year reaching $410.5 million, marking significant year-over-year growth [24][29] - FILSPARI generated approximately $103 million in net product sales for Q4 2025, resulting in $322 million for the full year, representing a 144% year-over-year growth [19][24] - The company achieved a net income of $2.7 million for Q4 2025, compared to a net loss of $60.3 million for the same period in 2024 [29] Business Line Data and Key Metrics Changes - FILSPARI saw record demand with 908 new patient starts in Q4 2025, driven by strong physician adoption and confidence in its role as a foundational therapy in IgA nephropathy [18][19] - Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 2025, totaling $88.5 million for the full year [25] Market Data and Key Metrics Changes - The company noted that over 96% of the patient population has a pathway to reimbursement for FILSPARI, maintaining a strong position in payer boundaries despite new competition [37] - There is increasing adoption of FILSPARI among patients with proteinuria levels below 1.5 grams per gram, which represents approximately two-thirds of the addressable IgA nephropathy population [21] Company Strategy and Development Direction - The company aims to solidify FILSPARI's foundational role in IgA nephropathy, successfully deliver the first approved medicine for FSGS, and advance enrollment in the Phase 3 HARMONY Study [9][30] - The strategy includes building a durable, growing rare disease company grounded in execution and scientific rigor, with a focus on delivering meaningful progress for patients [9][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical profile of FILSPARI as a potential FSGS therapy, despite a shift in the FDA's PDUFA action date to April 13, 2026 [8][12] - The company anticipates continued strong demand for FILSPARI and expects meaningful net product sales growth in 2026, despite modestly higher gross to net discounts [30][31] Other Important Information - The company has resumed activating clinical trial sites for the Phase 3 HARMONY study for pegtibatinase, which is designed to evaluate sustained total homocysteine control in classical homocystinuria [16] - The company reported a total of approximately $322.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025 [29] Q&A Session Summary Question: Can you provide more detail on the IgA performance and how the product is being prescribed? - Management noted that demand was driven by modifications in REMS requirements and the publication of KDIGO guidelines, with the majority of utilization occurring in community-based nephrologists [35][37] Question: Have you had more significant data requests from the FDA? - Management confirmed ongoing engagement with the FDA and stated that they are on track for the April 13 action date, without providing specific details on the nature of the requests [46] Question: What proportion of new patient starts came from patients with proteinuria less than 1.5 grams per gram? - Management indicated that there is an increasing proportion of patient start forms with proteinuria levels below 1.5, although specific percentages were not disclosed [50][53] Question: What are your plans for communicating with the investor community as you approach the FSGS PDUFA? - Management stated they will enter a quiet period and provide updates following any material communication from the FDA regarding the PDUFA action [85] Question: Can you set expectations for first quarter demand relative to Q4 2025? - Management expressed confidence in strong demand exceeding 900 new patient starts but cautioned about variability in a rare disease market [90]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported U.S. net product sales of $126.6 million, with total net product sales for the full year reaching $410.5 million, marking significant year-over-year growth [24][29] - FILSPARI generated approximately $103 million in net product sales for Q4 2025, resulting in $322 million for the full year, representing a 144% year-over-year growth [19][24] - The company achieved a net income of $2.7 million for Q4 2025, compared to a net loss of $60.3 million for the same period in 2024 [29] Business Line Data and Key Metrics Changes - FILSPARI saw record demand with 908 new patient starts in Q4 2025, driven by strong physician adoption and confidence in its role as a foundational therapy in IgA nephropathy [18][19] - Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 2025, totaling $88.5 million for the full year [25] Market Data and Key Metrics Changes - The company noted that over 96% of the patient population has a pathway to reimbursement for FILSPARI, indicating strong payer support despite new competition [37] - There is increasing adoption of FILSPARI among patients with proteinuria levels below 1.5 grams per gram, which represents approximately two-thirds of the addressable IgA nephropathy population [21] Company Strategy and Development Direction - The company aims to solidify FILSPARI's foundational role in IgA nephropathy, successfully deliver the first approved medicine for FSGS, and advance enrollment in the Phase 3 HARMONY Study [9][30] - The strategy includes expanding the commercial team and preparing for a potential launch in FSGS, which is expected to be a larger opportunity compared to IgA nephropathy [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of FILSPARI in IgA nephropathy and the potential for FSGS, emphasizing the urgency to deliver meaningful progress for patients [5][32] - The company anticipates meaningful net product sales growth from FILSPARI and IgA nephropathy, with a focus on thoughtful investments to support long-term growth [30][31] Other Important Information - The company received a major amendment notification for its sNDA for FSGS, with a new FDA PDUFA target action date set for April 13, 2026 [7][8] - Pegtibatinase for classical homocystinuria is also advancing, with resumed site activation for the pivotal Phase 3 HARMONY study [8][16] Q&A Session Summary Question: Can you provide more detail on IgA performance and the prescribing landscape? - Management noted strong demand driven by REMS modifications and KDIGO publication, with the majority of utilization occurring in community settings [35][37] Question: Have there been significant data requests from the FDA regarding FSGS? - Management confirmed ongoing engagement with the FDA and expressed confidence in the data supporting FILSPARI's potential treatment for FSGS [46][68] Question: What is the sales infrastructure for IgAN and how will it expand for FSGS? - The prescriber base for FSGS is similar to IgA nephropathy, with an expanded field team already operational to optimize opportunities [57][60] Question: How do you view FILSPARI's market penetration and growth potential? - Management indicated that FILSPARI has not yet penetrated 10% of the addressable patient population, suggesting significant growth opportunities ahead [77][80]

Financial Data and Key Metrics Changes - For Q4 2025, Travere reported U.S. net product sales of $126.6 million, with total net product sales for the full year reaching $410.5 million, marking significant year-over-year growth [21][22] - FILSPARI generated approximately $103 million in net product sales for Q4 2025, resulting in $322 million for the full year, representing a 144% year-over-year growth [17][21] - Net income for Q4 2025 was $2.7 million, or $0.03 per basic share, compared to a net loss of $60.3 million, or $0.73 per basic share, for the same period in 2024 [25] Business Line Data and Key Metrics Changes - FILSPARI saw record demand with 908 new patient starts in Q4 2025, driven by strong physician adoption and confidence in its role as a foundational therapy for IgA nephropathy [16][17] - Thiola and Thiola EC contributed $23.3 million in U.S. net product sales during Q4 2025, totaling $88.5 million for the full year [22] Market Data and Key Metrics Changes - The demand for FILSPARI continued strongly into Q1 2026, indicating robust growth potential despite new competition entering the market [19][39] - The company reported that over 96% of the patient population has a pathway to reimbursement for FILSPARI, maintaining a strong position in payer boundaries [33] Company Strategy and Development Direction - Travere aims to solidify FILSPARI's foundational role in IgA nephropathy, successfully deliver the first approved medicine for FSGS, and advance enrollment in the Phase 3 HARMONY Study [7][28] - The company is focused on building a durable, growing rare disease company grounded in execution and scientific rigor, with a commitment to delivering meaningful progress for patients [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical profile of FILSPARI as a potential FSGS therapy, despite a shift in the FDA's PDUFA target action date to April 13, 2026 [6][9] - The company anticipates continued growth in net product sales from FILSPARI and IgA nephropathy, with a strong balance sheet and no near-term need for additional capital [26][27] Other Important Information - The company has resumed site activation for the pivotal Phase 3 HARMONY study for pegtibatinase, which is expected to become the first disease-modifying therapy for classical homocystinuria [13][15] - Travere's strong commercial execution in Q4 2025 was evidenced by record demand and revenue, positioning the company well for sustainable growth [19][20] Q&A Session Summary Question: Can you provide more detail on the IgA performance and how the product is being prescribed? - Management noted that the strong demand in Q4 was driven by modifications in REMS requirements and the publication of KDIGO guidelines, with the majority of utilization occurring in community-based nephrologists [31][33] Question: Have you had more significant data requests from the FDA? - Management confirmed ongoing engagement with the FDA and provided requested information, remaining on track for the April 13 PDUFA date [41][42] Question: What proportion of new patient starts came from patients with proteinuria less than 1.5 grams? - Management indicated that there is an increasing proportion of patient start forms with proteinuria levels below 1.5 grams, although specific percentages were not provided [46][49] Question: What are your plans for communicating with the investor community as you approach the FSGS PDUFA? - Management stated they will enter a quiet period and provide updates following the FDA's decision, similar to previous communications [78][80] Question: Can you set expectations for Q1 as it relates to new patient starts? - Management expressed confidence in strong demand exceeding 900 new patient starts, but noted variability is expected in rare disease markets [84][85]

Summary of Travere Therapeutics Conference Call Company Overview - **Company**: Travere Therapeutics (NasdaqGM:TVTX) - **Focus**: Rare diseases, specifically targeting IgA nephropathy, FSGS, and homocystinuria (HCU) [2][3] Key Points Product Development and Regulatory Updates - **FILSPARI**: - Launched for IgA nephropathy, aiming to replace traditional treatments like RAS inhibitors and ARBs [3] - Achieved record commercial performance in the last quarter, marking the strongest quarter to date [3] - sNDA under review for FSGS, with a PDUFA date extended to April 13, 2026, due to additional information requests from the FDA [3][6] - Anticipated to be the first approved treatment for FSGS, addressing a significant unmet need [3][6] - **HCU**: - Manufacturing challenges resolved, with plans to restart Phase III HARMONY study [4] - HCU is a genetic metabolic disease with significant health risks if untreated, including cognitive and psychiatric defects [34][35] Market Dynamics and Competitive Landscape - **FSGS Market**: - High confidence in the approvability of sparsentan for FSGS due to strong clinical trial results [6][10] - Anticipated rapid uptake post-approval, driven by urgency and prior experience with FILSPARI in IgA nephropathy [12][31] - Expectation of complementary therapies rather than direct competition in the FSGS space [19] - **IgA Nephropathy**: - Increased competition in the market, but Travere believes that the introduction of new therapies will expand the overall market rather than diminish FILSPARI's growth [21][22] - Observing a trend towards earlier treatment and combination therapies in line with updated treatment guidelines [22] Financial Position and Future Outlook - **Financial Health**: - End of year cash position at $323 million, sufficient to support ongoing operations and product launches without immediate capital needs [45][46] - **Long-term Strategy**: - Plans to pursue additional assets post-FSGS approval, focusing on synergies with existing development and commercial expertise [43][44] Other Important Insights - **Patient Compliance**: High persistence rates observed for FILSPARI, attributed to its once-daily dosing and positive patient outcomes [27] - **REMS Program**: Adjustments to the REMS program have positively impacted prescribing behavior, allowing for quarterly testing instead of monthly [28][29] - **Payer Dynamics**: Early indications show payers are supportive of combination therapies, which may enhance FILSPARI's market position [24][25] Conclusion Travere Therapeutics is positioned for significant growth with its focus on rare diseases, particularly with the anticipated approval of FILSPARI for FSGS. The company is well-capitalized and strategically planning for future developments while navigating a competitive landscape in the rare disease market.

Summary of Travere Therapeutics FY Conference Call Company Overview - **Company**: Travere Therapeutics (NasdaqGM:TVTX) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **CEO**: Eric Dube Key Points Industry and Company Focus - Travere Therapeutics is focused on rare diseases, particularly in the areas of IgA nephropathy, FSGS (Focal Segmental Glomerulosclerosis), and homocystinuria (HCU) [2][3][32] Financial Performance - Achieved **$410 million** in net revenue for 2025, with **143% growth** compared to 2024 [3][4] - Revenue breakdown: **$323 million** from Filspari and **$88 million** from the Thiola portfolio [4] - **$103 million** revenue in Q4 2025, representing **108% growth** year-over-year [13] Product Updates - **Filspari**: - Reached an all-time high of **908 new patient start forms** in Q4 2025 for IgA nephropathy [3][12] - Positioned as a foundational therapy for IgA nephropathy, with a unique once-a-day pill formulation [10][11] - Clinical data shows a **50% reduction** in proteinuria compared to the standard of care [25] - Anticipated FDA approval for FSGS, with ongoing regulatory engagement [5][6][30] - **HARMONY Study**: - Phase III program for HCU reinitiated, focusing on enzyme replacement therapy [4][32] - Current treatment options are limited, with a significant unmet need for disease-modifying therapies [33] Regulatory Engagement - Ongoing discussions with the FDA regarding the FSGS supplemental new drug application (SNDA) [5][6] - Received additional information requests from the FDA focused on clinical benefits of Filspari, not related to safety or manufacturing [5][41] Market Opportunity - Approximately **70,000 patients** diagnosed with IgA nephropathy in the U.S., with a significant number still untreated [10] - Filspari is expected to capture a larger market share as awareness and clinical use grow [30][17] - The company has not yet reached **10%** of the addressable population for IgA nephropathy, indicating substantial growth potential [16][17] Clinical Insights - The KDIGO guidelines have been updated to reflect the urgency of treating IgA nephropathy, emphasizing the need for earlier intervention [9][15] - The PARASOL Group's findings indicate that reducing proteinuria is critical for lowering the risk of kidney failure in FSGS patients [21][23] Future Outlook - Travere is committed to redefining the standard of care in IgA nephropathy, FSGS, and HCU, with a strong financial foundation to support ongoing initiatives [37][52] - The company is prepared for rapid uptake of Filspari in FSGS upon approval, leveraging existing relationships with nephrologists [30][31] Patient-Centric Approach - The company emphasizes a patient-inspired approach, with personal connections to rare diseases among its team members [2] - Highlighted the story of a patient, Jennifer, to illustrate the impact of FSGS and the need for innovative therapies [38][39] Additional Important Information - The company has a strong commitment to the rare disease community and aims to provide hope and better treatment options for patients [39][52] - The upcoming PDUFA date for FSGS is critical, with expectations for timely communication regarding FDA decisions [40][41]

Core Insights - Travere Therapeutics anticipates approximately $127 million in U.S. net product sales for Q4 2025 and around $410 million for the fiscal year 2025, ending the year with about $323 million in cash and equivalents [1][6][7] Corporate Update - The company reported a record number of patients treated with FILSPARI for IgA Nephropathy (IgAN), emphasizing its foundational role in therapy [2] - Travere is preparing for the potential commercial launch of FILSPARI in Focal Segmental Glomerulosclerosis (FSGS), which would be the first approved medication for this condition [2][6] - The pivotal Phase 3 HARMONY Study of pegtibatinase is set to restart in Q1 2026 following manufacturing optimizations [5] Financial Performance - Preliminary U.S. net product sales of FILSPARI reached approximately $103 million in Q4 2025, marking a 108% year-over-year growth, with total sales for 2025 around $322 million [6] - The company received a $40 million milestone payment from CSL Vifor for market access achievements, with FILSPARI launched in several European countries [6] Regulatory and Development Milestones - The PDUFA target action date for the supplemental New Drug Application (sNDA) for FILSPARI in FSGS is set for January 13, 2026 [6] - The company is generating clinical evidence to support FILSPARI's role in IgAN through ongoing studies and presentations at medical meetings [6] - Chugai Pharmaceutical plans to submit a New Drug Application for sparsentan in Japan in 2026, with Travere eligible for additional milestone payments [6]

Summary of Travere Therapeutics FY Conference Call Company Overview - **Company**: Travere Therapeutics (NasdaqGM:TVTX) - **Date**: December 02, 2025 - **Key Focus**: The company is focused on the ongoing launch of FILSPARI for IgA nephropathy, an SNDA with the FDA for FSGS, and enzyme replacement therapy for classical homocystinuria (HCU) [2][3][4] Core Points and Arguments FILSPARI Launch and Growth - **IgA Nephropathy**: The launch of FILSPARI is seeing strong growth, supported by the nephrology community and recent KDIGO guidelines that emphasize urgency in treating patients to prevent kidney failure [2] - **Patient Reach**: The company has reached a significant number of new patients this year, indicating robust market acceptance [2] FSGS SNDA and Regulatory Process - **SNDA Submission**: An SNDA for FSGS is under review, with a PDUFA date set for January 13, 2026. The process is straightforward, with no mid-cycle or late-cycle meetings planned [3][4] - **Labeling Expectations**: The company anticipates a broad indication for FSGS treatment without specific proteinuria cutoffs, as many patients present with high proteinuria levels [6][9] Market Potential and Patient Population - **Addressable Population**: The estimated addressable population for FSGS is around 30,000 patients, which could expand to 40,000-50,000 if secondary patients are included [10][9] - **Provider and Payer Dynamics**: Nephrologists are eager to prescribe FILSPARI, especially for secondary patients, despite challenges in identifying the etiology of FSGS. Payers may face difficulties in managing secondary populations due to the lack of specific ICD-10 codes [11][12][13] Manufacturing and Enrollment Challenges - **HCU Therapy**: The company faced manufacturing scale-up challenges but is now on track to resume enrollment in the phase three trial for pegtibatinase for HCU next year [3][26] - **Patient Support**: The company emphasizes the importance of patient support services to help patients reach target doses and maintain compliance [16][18] Financial Dynamics - **Revenue Growth**: Revenue from FILSPARI is outpacing patient start forms, attributed to the time required for reimbursement processes post-approval [19][20] - **Future Expectations**: The company expects a more stable dynamic between new patient prescriptions and reimbursements moving forward [21][23] Combination Therapy Considerations - **Combination with BAFF APRIL**: The company is optimistic about the potential for payers to approve FILSPARI in combination with BAFF APRIL therapies, especially for severe patients [24][25] HCU Study Design - **Enrollment Cadence**: The company plans to quickly ramp up enrollment for the HCU trial, having already identified interested patients and providers [26] - **Dietary Protocol**: A sub-study will explore how much protein can be introduced into patients' diets while maintaining control of homocysteine levels, which is a significant concern for patients [27][28] Other Important Points - **Eagerness for Approval**: There is a high level of eagerness among physicians to prescribe FILSPARI for FSGS, indicating a strong unmet need in the market [18] - **Patient-Centric Approach**: The company is focused on addressing patient needs, particularly in terms of dietary flexibility and treatment efficacy [27][28] This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic priorities, market dynamics, and future expectations.